Dysfunctional cognitions, emotions, or behaviours (participant rated) at end of treatment Whitely Index · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · people with somatoform disorders and medically unexplained physical symptoms
Psychological therapy may leads to higher treatment response at end of treatment CGI‐improvement/Global… compared with usual care or waiting list (low certainty).
1 finding from 1 review
Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Healthcare use · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Severity of somatic symptoms at end of treatment · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Secondary outcome: acceptability of treatment · people with somatoform disorders and medically unexplained physical symptoms
Psychological therapy showed no clear difference in acceptability 1 ‐ proportion of participants withdrawing during… compared with enhanced or structured care (moderate certainty).
1 finding from 1 review
Dysfunctional cognitions, emotions, or behaviours at end of treatment Whitely Index (different forms) · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Adverse events ‐ Withdrawn for medical reasons · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants probably leads to higher adverse events ‐ Withdrawn for medical reasons compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Withdrawn for medical reasons: Tricyclics versus placebo · patients with depression during opioid agonist treatment for opioid dependence
The intervention leads to higher adverse events ‐ Withdrawn for medical reasons: Tricyclics versus… (high certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Withdrawn for medical reasons: SSRI versus placebo · patients with depression during opioid agonist treatment for opioid dependence
The intervention showed no clear difference in adverse events ‐ Withdrawn for medical reasons: SSRI versus placebo (high certainty).
1 finding from 1 review
Adverse events ‐ Withdrawn for medical reasons · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants probably leads to higher adverse events ‐ Withdrawn for medical reasons compared with placebo according to any definition (moderate certainty).
1 finding from 1 review
All‐cause mortality · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether portosystemic shunts changes all‐cause mortality compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes all‐cause mortality compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether portosystemic shunts changes rebleeding compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes rebleeding compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with cirrhosis and with previous oesophagogastric variceal bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality due to rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes mortality due to rebleeding compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Acute hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes acute hepatic encephalopathy compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Chronic hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes chronic hepatic encephalopathy compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with cirrhosis and with previous oesophagogastric variceal bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found